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Abstract
Immunoliposomes have been prepared using antibodies raised to an antigenic determinant on the cell surface of the oral
 .bacterium Streptococcus oralis S. oralis in an investigation of their potential to reduce dental plaque. The N-succi-
 .nimidyl-S-acetylthioacetate SATA derivative of the antibodies were conjugated through the reactive m-maleimidobenzoyl-
 .  .N-hydroxysuccinimide MBS derivative of dipalmitoyl-phosphatidylethanolamine DPPE incorporated into liposomes. The
degree of antibody conjugation to the liposomes was controlled by the percentage of DPPEMBS incorporated into the
liposomes. The chemical modification of the antibodies did not affect the ability of the antibodies to bind to a S. oralis
biofilm. However, the affinity of the immunoliposomes for S. oralis was much lower than that of the free antibody. The
anti-oralis antibodies were highly specific for S. oralis. The anti-oralis immunoliposomes showed the greatest affinity for
S. oralis, when targeted to a range of different oral bacterial biofilms. The immunoliposome targeting affinity for S. oralis
was largely unaffected by the number of antibodies conjugated to the liposomal surface or by the net charge of the
 .liposomal lipid bilayer. The immunoliposomes showed a greater affinity for S. oralis than ‘naked’ bearing no antibody
liposomes. However, positively charged liposomes, incorporating stearylamine, adsorbed to S. oralis with greater affinities
than the immunoliposomes. The immunoliposomes appeared to be physically stable over a period of 18 months, as judged
by particle-size measurements. q 1998 Elsevier Science B.V.
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1. Introduction
Liposomes are versatile drug delivery systems that
have great potential in the treatment of infectious
w xdiseases 1 . The use of liposomes in the biological
milieu enables large quantities of drug to be protected
and carried to target specific sites. As phagocytic
 .cells of the reticuloendothelial system RES are the
natural targets of liposomes injected intravenously
w x2 , antibiotics entrapped in liposomes have been
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investigated mainly in infections due to intracellular
 .microbes including parasites such as Salmonella,
w xMycobacterium, and Leishmania 3 . In vivo use of
liposomes in the delivery of antimicrobial agents
outside the RES can be achieved by manipulation of
w xthe liposome size and composition 4 . For example,
antibiotic has been successfully targeted, using lipo-
somes, to lung tissue infected with Klebsiella pneu-
w xmoniae 5 . Liposome targeting to strains of skin-as-
sociated and oral bacteria has been investigated using
a number of different approaches. They include using
w xliposomes with surface bound lectins 6–8 , lipo-
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somes prepared from lipid mixtures incorporating
w xnegatively charged phosphatidylinositol 9,10 , posi-
tively charged liposomes incorporating stearylamine
w x11 and liposomes with surface bound antibodies
w x12 . Monoclonal antibodies have potential as highly
w xspecific targeting vehicles 13 and can be easily
produced against determinants of bacterial cell sur-
faces. Dental plaque is a key factor in dental caries
w xand periodontal disease 14 . Both diseases may be
prevented by effectively controlling plaque develop-
ment. As specific oral bacteria are known to be initial
colonisers of the tooth surface, a logical way to
control plaque development bacteria is to use im-
munoliposomes for specific delivery of non-specific
antimicrobial agents to early tooth colonisers.
In this study, we have prepared and characterized
immunoliposomes with two different surface-bound
monoclonal antibodies raised to antigenic determi-
nants on the surface of Streptococcus oralis for-
w x.mally Streptococcus sanguis 15 , a predominant
w xinitial colonizer of the tooth surface 14 . The N-
 .succinimidyl-S-acetylthioacetate SATA derivatives
of the antibodies were conjugated through the reac-
tive m-maleimidobenzoyl-N-hydroxysuccinimide
 .M B S d eriv a tiv e o f d ip a lm ito y lp h o s -
 .phatidylethanolamine DPPE incorporated into lipo-
somes prepared by the vesicle extrusion technique
w x16 . The targeting specificity and affinity of the
anti-oralis immunoliposomes to films of oral bacteria
adsorbed on solid surfaces has been investigated with
a view to using immunoliposomes as a potential
means of delivering antimicrobial agents to the oral
environment. A preliminary abstract of this work has
w xbeen published 12 .
2. Materials and methods
L-a-dipalmitoylphosphatidylethanolamine DPPE,
.product No. P-0890 , L-a-dipalmitoylphosphatidyl-
 .choline DPPC, product No. P-0763 , cholesterol
 . Chol, product No. C-8667 and stearylamine SA,
. product No. S-9273 were from Sigma Poole, Dorset,
.  .UK . Phosphatidylinositol PI grade 1 was from
 . w3 xLipid Products South Nutfield, Surrey, UK . H -
 .DPPC TRK.673 was from Amersham International
 .Aylesbury, Buckinghamshire, UK . The liposome
extruder was from Lipex Biomembranes Vancouver,
.  .British Columbia . Poretic filters pore size 100 nm
 .were from Poretics Livermore. CA . N-succi-
 .nimidyl-S-acetylthioacetate SATA was obtained
 .from Calbiochem Cambridge, UK . M-maleimido-
benzoyl-N-hydroxysuccinimide ester MBS, product
. No. 22310 and sulpho-succinidyl 4- p-maleimi-
. dophenyl butyrate sulpho-SMPB, product No.
. 22318 were from Pierce and Warriner Chester,
.  .UK . Triethylamine product No. 23,962-3 was ob-
 .tained from Aldrich Gillingham, Dorset, UK . Hy-
 .droxylamine product No. H 9876 was obtained
 .from Sigma Poole, Dorset, UK .
Two different antibodies 4718 and 4715 batch
.No. PL772 and PL779, respectively , raised in mouse
to S. oralis were gifts from Unilever Research Col-
.worth Laboratory, Bedford, UK . Alkaline phos-
 .phatase rabbit anti-mouse IgG product No. A-1902
and Sigma 104 phosphatase substrate tablets were
 .obtained from Sigma Poole, Dorset, UK . Strepto-
 .coccus oralis Streptococcus sanguis strain 209 was
a gift from Unilever Research Port Sunlight Labora-
.tories, Wirral, Merseyside, UK . Streptococcus mu-
tans strain D282, Streptococcus sanguis strain C104,
Streptococcus gordonii Streptococcus sanguis strain
.Cr2B and Streptococcus sali˝arius strains DBD and
NCTC 8618 were from the Manchester University
 .collection. Brain heart infusion code CM255 , yeast
 .extract powder code L21 and phosphate buffered
 . saline PBS tablets were from Oxoid Basingstoke,
.Hampshire. UK . Blood agar plates were obtained
from Manchester Royal Infirmary Clinical Sciences
.Building, Manchester . All other reagents and sol-
vents were of analytical grade and made up in double
distilled water.
( )2.1. Preparation of reacti˝e lipid DPPEMBS and
the SATA deri˝ati˝es of anti-oralis antibodies 4718
and 4715
 .The MBS derivative of DPPE DPPEMBS was
w xprepared as previously described 17 . The SATA-de-
rivatised anti-oralis antibodies were prepared by a
w xmodification of the method of Duncan et al. 18 .
SATA 2.5 ml of 18.8% SATA in dimethylform-
.  .amide was added to antibody 10 mg in PBS . After
15 min, the derivatised antibody was separated from
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unreacted SATA by gel filtration on a Sephadex G50
 .column 15=2 cm . The quantity of antibody col-
lected was assayed by the protein assay method of
w xLowry 19 .
( )2.2. Preparation of ˝esicles by extrusion VETs
 .Lipid mixtures total mass 30–38 mg plus 5 mCi
w3 xH -DPPC were dissolved in dry chloroform
 .methanol 4 : 1 by volume in a round-bottomed flask.
The solvent was removed by rotary evaporation at
608C to leave a uniform layer of dry lipid. PBS 3 ml,
.608C was added to form multilamellar vesicles
 .MLVs . The vesicles were then extruded 5–10 times,
under pressurised N gas, through 100 nm filters2
using an extruder, producing VETs vesicles pro-
.duced by extrusion techniques . Samples of the VETs
were taken for scintillation counting and for sizing by
photon-correlation spectroscopy using a Malvern
RR146 autosizer.
2.3. Preparation and characterisation of immunolipo-
somes
Deacetylation of antibody bound SATA was car-
ried out using hydroxylamine solution 0.5 M
NH OH, 25 mM EDTA plus solid Na HPO to pH2 2 4
.7.4 to give a final concentration of 0.1 M hydroxyl-
amine in the SATA-derivatised antibody solution for
1 h. The sulphydryl content of the deacetylated
derivative was determined by the method of Ellman
w x20 . SATA derivatised and deacetylated antibody
 .1 mg was added to VETs containing DPPEMBS.
The mixture was left overnight at 48C, then applied to
 .a Sepharose 4B gel filtration column 25=2 cm .
 .Fractions 2.2 ml were collected and assayed for
 .lipid concentration by scintillation counting and
total protein concentration bound, and unbound anti-
. w xbody by the method of Wang and Smith 21 . The
weight average number of antibody molecules per
 . w ximmunoliposome P , described previously 7 , wasw
calculated from the protein concentration and the
liposome size distribution fitted to a normal weight
distribution.
2.4. Preparation of bacterial biofilms
Bacteria were stored at y708C in glycerol or
semi-skimmed milk. Streaked blood agar plates were
incubated upside down at 378C for 18 h in a candle
jar, then stored for one month at 48C. Bacteria were
 .grown for 18 h at 378C in brain heart infusion BHI
broth 3.7% BHI, 0.3% yeast extract plus 1% su-
.crose , then harvested by centrifugation and washed
four times in sterile PBS. The final bacterial suspen-
 .sion O.D s0.5 was loaded into microtitre plate550
 .wells 200 ml each well and left overnight at room
temperature for the cells to adhere. Before use, the
 .plates were washed 3=300 ml with PBS.
( )2.5. Enzyme-linked immunosorbent assay ELISA
Microtitre plates of bacterial biofilms were incu-
 .bated with BSA 1% in PBS for 15 min at room
temperature. The plates were then washed 3=300 ml
.PBS and incubated with free anti-oralis antibody,
derivatised free anti-oralis antibody, anti-oralis im-
 .munoliposomes or a PBS control 200 ml . After 2 h
 .at 378C, the plates were washed 3=300 ml PBS
and incubated for 1 h at 378C with a second antibody
 .conjugate 200 ml, diluted 1 : 1000 in PBS . The plates
 .were then washed again 3=300 ml PBS and incu-
bated with substrate 100 ml, two tablets in 10 ml
9.7% diethanolamine, 0.01% MgCl .6H O buffer,2 2
.pH 9.8 . The plate was then read at 410 nm using a
plate reader Dynatech MR610 coupled to an Apple
.IIe microcomputer .
2.6. Targeting assay
To measure the targeting of the liposomes to the
biofilms, microtitre plates of bacterial biofilms were
 .first blocked with BSA 1% in PBS for 15 min at
room temperature. In the experiments with cationic
liposomes, blocking with BSA was omitted. The
 .plates were then washed 3=300 ml PBS and incu-
 .bated with liposomes 200 ml at various concentra-
tions for 2 h at 378C. The plates were washed again
 .3=300 ml PBS and the targeted vesicles, adsorbed
 .to the biofilms, were solubilised by SDS 5%, 200 ml .
After 30 min the plates were sonicated in a water bath
for 5 min and 180 ml of the SDS solution was taken
for scintillation counting. The results of the targeting
assay are expressed in terms of percentage monolayer
 .coverage %amc given by:
%amcs N rL =100 1 .  .obs a
where N is the measured number of moles of lipidobs
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adsorbed to the biofilm and L the number of molesa
that would be adsorbed if the biofilm was covered
with a close-packed monolayer of liposomes. L wasa
calculated from the following equation:
2L s A rp d r2 = N 2 . . /w wa bf
where d is the weight-average diameter of the lipo-w
somes having a weight-average number of lipid
molecules per liposome of N and A the geometricbfw
area of the biofilm. For unilameller liposomes N canw
be calculated from d assuming an area per lipidw
molecule in the liposomal bilayer of 50 nm2 and a
bilayer thickness of 7.5 nm as previously described
w x23 . The area of the biofilm was taken as 2.202=
10y4 m2 which was measured in a previous study for
the surface of the microtitre plate wells exposed to
w x200 ml of solution 24 .
3. Results
3.1. Characterisation of immunoliposomes
SATA was found to introduce an average of 1.75
and 1.03 sulphydryl groups into the anti-oralis anti-
bodies 4718 and 4715 respectively. Separation of
unbound SATA-derivatised anti-oralis antibody from
VETs with covalently conjugated anti-oralis antibody
was achieved by elution through a Sepharose 4B
column; typically f40% of the total antibody was
associated with the VETs. The extent of antibody
conjugation is controlled by the percentage of reac-
tive lipid DPPEMBS in the liposome mixture. The
weight average number of proteins per liposome, Pw
w x7 , increases with increasing percentage of
 .DPPEMBS in the VETs as shown in Fig. 1 A . Both,
anti-oralis antibodies 4718 and 4715 show the same
extent of conjugation with increasing DPPEMBS.
While these results were reproducible with freshly
prepared materials, the extent of conjugation de-
creased on storage of the derivatised antibodies which
accounts for some of the lower values of P for aw
given mol% DPPEMBS shown in Figs. 4 and 5.
Taking dimensions of antibody fragments from the
Brookhaven Protein Data Bank, the Y-shaped struc-
ture of an IgG has overall dimensions of 18.8 nm=
18.8 nm = 4.1 nm, irrespective of whether the
 .Fig. 1. Dependence of weight-average number of A – anti-oralis
 .  .antibody molecules per liposome P and B – surface area perw
anti-oralis antibody molecules on the surface of immunolipo-
somes as a function of the percentage of reactive lipid DP-
.  .PEMBS , by mass, in DPPCrPIrDPPEMBS VETs. ‘ –
 .Anti-oralis antibody 4715, and I – anti-oralis antibody 4718.
The error bars are from three experiments.
molecule lies flat or with the Fc or Fab regions
uppermost. Assuming rotational motion, the excluded
  .2. 2 w xsurface area p 18.8 is 1110 nm 22 . Increasing
the DPPEMBS content of the liposomes increases
conjugation of anti-oralis antibody until a minimum
area per antibody molecule of ; 1000 nm2 is
 .achieved. This is shown in Fig. 1 B . The results
suggest that a close-packed monolayer of antibody
molecules on the liposomal surface can be achieved
with a minimum DPPEMBS concentration of 17.5%.
Fig. 2 shows the adsorption of free anti-oralis
antibody, derivatised anti-oralis antibody and anti-
oralis immunoliposomes to a Streptococcus oralis
bacterial biofilm measured by an ELISA. A charac-
teristic sigmoidal antibody dilution curve of antibody
adsorbing to S. oralis is seen for free antibody,
SATA derivatised antibody, deacetylated antibody
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Fig. 2. Adsorption of free anti-oralis antibody 4718, chemically
modified anti-oralis antibody 4718 and anti-oralis 4718 immuno-
liposomes to S. oralis, measured by an ELISA. Antibody target-
 .ing 2 h at 378C. P for immunoliposomes s47. ‘ – Freew
 .  .antibody, I – SATA-derivatised antibody, n SATA-deriva-
 .tised antibody plus hydroxylamine, = – SATA-derivatised
 .antibody plus hydroxylamine plus sulpho-SMPB, and v –
antibody conjugated to DPPCrPIrDPPEMBS VETs.
and SATA derivatised antibody conjugated to
sulpho-SMPB through a thioether cross-linkage. For
antibody conjugated to liposomes incorporating
DPPEMBS, the sigmoidal antibody adsorption curve
is displaced to the right by approximately three or-
ders of magnitude in terms of antibody concentration.
Thus, the antibody concentration required for im-
munoliposome adsorption is approximately 1000
times greater than that required for an equivalent
ELISA signal measuring free antibody adsorption.
3.2. Specificity of anti-oralis immunoliposomes
The affinity of free anti-oralis antibodies 4718 and
4715 for various bacterial biofilms was assessed us-
ing an ELISA method. The results are shown in Fig.
3. A characteristic sigmoidal antibody dilution curve
is found for each antibody adsorbing to Streptococ-
cus oralis. About half of S. oralis’s antigenic sites
are occupied when antibody concentrations in the
order of 0.1 mg mly1 are used and the antigenic sites
are completely saturated using antibody concentra-
tions in the order of 1 mg mly1. For anti-oralis anti-
 .body clone 4718 Fig. 3A , there is a slight cross
reaction with the bacterium S. sanguis C104, and
slightly more so with S. gordonii. The anti-oralis
antibody 4718 does not bind significantly to S. sali-
˝arius DBD, S. sali˝arius 8618 or S. mutans D282.
 .For anti-oralis antibody clone 4715 Fig. 3B , there
is no cross reaction with other bacteria, but at high
 y1.antibody concentrations 0.1 mg ml the antibody
begins to bind non-specifically to all the bacterial
biofilms.
The affinity of anti-oralis immunoliposomes for
various bacterial biofilms was measured using the
targeting assay. The results of targeting anti-oralis
4718 immunoliposomes and anti-oralis 4715 im-
munoliposomes to five different oral bacteria are
 .  .shown in Fig. 4 A and B , respectively. Anti-oralis
4718 immunoliposomes adsorb with twice the affin-
ity to S. oralis than to other bacteria. Anti-oralis
4715 immunoliposomes adsorb with more than three
times the affinity to S. oralis than to other bacteria.
Non-specific adsorption of anti-oralis immunolipo-
somes to other bacteria results in f8% monolayer
coverages of the bacterial biofilms after 2 h at 378C.
 .  .Fig. 3. Affinity of anti-oralis antibodies A 4718 and B 4715
for various oral bacteria. Anti-oralis antibody incubation 2 h at
378C, anti-mouse alkaline phosphatase antibody incubation 1 h at
 .  .  .378C. v – S. oralis, I – S. gordonii, n – S. sanguis
 .  .C104, = – S. sali˝arius DBD, e – S. sali˝arius 8618, and
 .‘ – S. mutans D282.
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Fig. 4. Adsorption of anti-oralis immunoliposomes to various
oral bacteria. Targeting 2 h at 378C, lipid concentration 2 mM.
 .A –Anti-oralis 4718 VETs, liposome composition
 .DPPCrPIrDPPEMBS 82.8: 2.6 : 14.6, molar ratio , d sw
 .120nm, P s38. B – Anti-oralis 4715 VETs, liposome com-w
 .position DPPCrPIrDPPEMBS 82.8 : 2.6 : 14.6, molar ratio , dw
s117nm, P s17. The error bars are from four experiments.w
This adsorption is likely to be a result of lipid, rather
than antibody, interactions as the free antibody ad-
sorption to these bacteria is almost negligible Fig.
 .  ..3 A and B .
3.3. Affinity of anti-oralis immunoliposomes
Fig. 5 shows how immunoliposome targeting is
dependent on liposome concentration, measured by
lipid content. Anti-oralis immunoliposome adsorp-
tion increases with increasing lipid concentration and
is saturable. Anti-oralis 4718 immunoliposomes ad-
sorb to S. oralis with approximately twice the affin-
 .ity of ‘naked’ liposomes Fig. 5A . Anti-oralis 4715
immunoliposomes adsorb to S. oralis with approxi-
mately five times the affinity of ‘naked’ liposomes.
Cationic liposomes adsorb to S. oralis with a greater
affinity than anti-oralis immunoliposomes and the
adsorption of cationic liposomes is dependent on the
percentage of cationic lipid incorporated into the
 .VETs preparation Fig. 5B . However, the targeting
affinity of anti-oralis immunoliposomes is not signif-
icantly influenced by the charge on the liposomal
 .lipid bilayer Fig. 6 . The affinity of anti-oralis im-
munoliposomes for S. oralis is not significantly dif-
ferent depending on the weight average number of
 .antibody molecules P conjugated, within the rangew
 .examined Fig. 6B . The weight average number of
 .Fig. 5. A Adsorption of anti-oralis antibody immunoliposomes,
compared with ‘naked’ liposomes, to a S. oralis biofilm as a
function of lipid concentration. Liposome composition
 .DPPCrPIrDPPEMBS 82.8 : 2.6 : 14.6, molar ratio . Targeting
 .2 h at 378C. B – Anti-oralis 4715 VETs, d s107nm, P sw w
 .  .5.3. v – Anti-oralis 4718 VETs, d s115nm, P s6.8, =w w
 .’Naked’ VETs, d s114nm. B – Adsorption of cationic vesi-w
cles, compared to anti-oralis immunoliposomes, to a S. oralis
biofilm as a function of liposome lipid concentration. Targeting
 .2 h at 378C. n – Cationic VETs DPPCrCholrSA
 .  .61.4 : 20.8 : 17.8 molar ratio , d s132nm, I Cationic VETsw
 .  .DPPCrCholrSA 72.3 : 24.1 : 3.6 molar ratio d s137nm, vw
– Anti-oralis 4718 immunoliposomes DPPCrPIrDPPEMBS
 .82.8 : 2.6 : 14.6, molar ratio d s112nm, P s30.0. The errorw w
bars are from four experiments.
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 .Fig. 6. A – Adsorption of anti-oralis 4718 immunoliposomes,
with various lipid compositions, to S. oralis as a function of
 .liposomal lipid concentration. Targeting 2 h at 378C. = –
 4Negatively charged VETs 2.6 mol% PI liposome composition
 .DPPCrPIrDPPEMBS 82.8 : 2.6 : 14.6, molar ratio , d sw
 .  4120nm, P s38, e – positively charged VETs 3.6 mol% SAw
liposom e com position DPPCrCholrSArDPPEM BS
 . 4  .59.0 : 24.9 : 3.6 : 12.5, molar ratio , d s109nm, P s44 , ‘w w
– neutral VETs liposome composition DPPCrDPPEMBS
 .  .85.0 : 15.0, molar ratio d s111nm, P s19. B – Adsorptionw w
of anti-oralis antibody 4715 immunoliposomes, bearing various
numbers of antibody molecules per liposome to a S. oralis
 .biofilm, as a function of lipid concentration. ‘ – Liposome
 .composition DPPCrPIrDPPEMBS 92.6 : 2.6 : 4.8 molar ratio ,
 .d s113 nm, P s9.7"2.7, I – liposome compositionw w
 .DPPCrPIrDPPEMBS 87.8 : 2.6 : 9.6 molar ratio , d s115nm,w
 .P s23.6"2.3, n – liposome composition DPPCrPIrDP-w
 .PEMBS 82.8 : 2.6 : 14.6, molar ratio , d s112nm, P s30.0w w
"5.9. The error bars are from four experiments.
antibodies per liposome is controlled by the percent-
 .age of reactive lipid DPPEMBS in the VETs prepa-
ration. The targeting curves for immunoliposomes
with P ’s of 9.7, 23.6 and 30.0 are all similar, only atw
 .high lipid concentrations 5 mM does there seem to
be a trend for targeting to be limited by the number
of antibody molecules on the liposomal surface. The
size of the anti-oralis immunoliposomes was moni-
tored over an 18 month period. They were found to
be physically stable, with no signficant changes in the
mean size or size distribution width.
4. Discusssion
The number of sulphydryl groups introduced into
the anti-oralis antibodies compares well with the
introduction of sulphydryl groups into other
molecules, used for liposome targeting, by the same
w xconjugation technique 22,23,25 . Conjugation of
anti-oralis antibodies to DPPEMBS increases as the
 .percentage of reactive lipid DPPEMBS in the vesi-
cles increases, in agreement with previous studies
w x17,25,26 .
The chemical modification of anti-oralis antibody
4718, in several ways which relate to the liposome
conjugation process, does not affect the ability of the
antibody to bind to a S. oralis biofilm. However,
anti-oralis 4718 immunoliposomes appear to adsorb
much less effectively than the chemically altered free
antibody. These results imply that it is the presence
of the liposome attached to the antibody that is
affecting the affinity of the immunoliposomes for the
biofilm and not the derivatisation of the antibody. It
is possible that this could be attributable to the
second ELISA antibody conjugate binding ineffi-
ciently to liposomally bound close-packed anti-oralis
antibody or to steric effects of the bulky liposomes in
the biofilm.
Anti-oralis antibodies 4718 and 4715 are found to
be very specific for the bacterium S. oralis. Even
with other S. sanguis bacteria, there is little cross
reaction S. oralis and S. gordonii were formally
w x.classed as S. sanguis 15 . Anti-oralis immunolipo-
somes are relatively less specific for S. oralis than
the free antibody because of the non-specific interac-
tions of the vesicles with the other bacteria. However,
the anti-oralis immunoliposomes are still found to
adsorb with the greatest affinity to S. oralis so that
antibody specificity is retained to a certain degree
after conjugation to the liposomes. S. sali˝arius DBD
shows the largest non-specific immunoliposome ad-
sorption. This can be attributed to its carrying fim-
briae, rather than fibrils as in the case of S. sali˝ar-
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. w xius 8618 , on its cell surface 27 which have been
w xassociated with hydrophobicity 28 , helping lipo-
some targeting.
It is unclear why anti-oralis 4715 immunolipo-
somes target to S. oralis with a greater affinity than
 .anti-oralis 4718 immunoliposomes Fig. 5A , since
both antibodies bind to antigens of the protein SSP5,
w xthe S. sanguis salivary agglutinin receptor 29 , also
found in S. oralis Unilever Research, personal com-
.munication . The targeting efficiency of immunolipo-
somes depends on the numbers of antibodies per
liposome only at high liposome concentrations. There
are several reports of immunoliposome binding being
influenced by the degree of antibody conjugation
w x30,31 .
By comparison with the affinity of cationic vesi-
cles for S. oralis, immunoliposomes show relatively
low binding affinities. Immunoliposome adsorption to
S. oralis is presumed to occur as a result of specific
interaction between the antibody and a specific cell
surface antigen. Cationic liposome adsorption to S.
oralis is likely to occur as a result of a non-specific
electrostatic forces. We have found that cationic lipo-
somes adsorb strongly to several other bacteria in-
w xcluding Staphylococcus epidermidis 32 and aureus.
Because most bacteria have a net negative charge on
w xthe cell surface 33 , cationic vesicle targeting is
likely to occur largely through an electrostatic inter-
action.
When anti-oralis immunoliposomes were prepared
from more than one type of lipid mixture, it was
found that targeting does not depend on the net
charge of the liposomal lipids, most likely because
antibody molecules conjugated to the liposomal sur-
face mask the net charge on the liposomal lipid
surface.
 .Both, chemical hydrolysis, oxidation and physi-
cal instability aggregation, phase separation in the
.bilayer, fusion, loss of encapsulated drug of lipo-
w xsomes on storage have been described in detail 34 .
Anti-oralis immunoliposomes appear physically sta-
ble with regards to the size distribution over an 18
month period although chemical stability and reten-
tion of antibody specificity and affinity require fur-
ther study.
In conclusion, liposomes can be specifically tar-
geted to oral bacteria by use of monoclonal antibod-
ies. This may prove to be of importance for specific
delivery of antimicrobial agents to oral bacteria for
specific plaque control. By selectively inhibiting bac-
teria implicated in dental caries and periodontal dis-
ease, or bacteria involved in early plaque develop-
ment, it is hypothesised that the ecological niche of
disease-causing bacteria is vacated and filled by other
more benign organisms of the oral flora, or that by
inhibiting initial tooth colonisers, plaque development
is slowed.
It is noteworthy that oral streptococci can be found
in other types of infection in immunologically com-
promised and neutropenic patients, such as septi-
caemia and the Adult Respiratory Distress Syndrome
w x35 . With improvements for stabilisation of lipo-
somes in the blood being made with polyethylene
 w x.glycol-immunoliposomes for review, see Ref. 36 ,
drug delivery to specific oral bacteria in systemic
infections, by use of specific immunoliposomes, may
also be of future importance.
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